Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

1. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. (Abstract)

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).To determine whether switching to ticagrelor monotherapy after 3

2020 JAMA

2. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Full Text available with Trip Pro

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo. Cancer

2020 Lancet

3. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline Full Text available with Trip Pro

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline Randomized Placebo-Controlled Trial of the Effects of Aspirin on Dementia and Cognitive Decline - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation Neurology Actions . 2020 Mar 25;10.1212/WNL.0000000000009277. doi: 10.1212/WNL.0000000000009277. Online ahead of print. Randomized Placebo-Controlled Trial of the Effects of Aspirin on Dementia and Cognitive Decline , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain

2020 EvidenceUpdates

4. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 May 19;75(19):2403-2413. doi: 10.1016/j.jacc.2020.03.008. Epub 2020 Mar 30. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, University of Florida College of Medicine

2020 EvidenceUpdates

5. Monotherapy with a P2Y<sub>12</sub> inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. (Abstract)

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention.In this systematic review and meta-analysis, all randomised trials comparing P2Y12 inhibitor with aspirin monotherapy for secondary prevention in patients (...) determining study inclusion (ie, cerebrovascular, coronary, or peripheral artery disease), P2Y12 inhibitor type and dosage, aspirin dosage, endpoint definitions, effect estimates, follow-up duration, and percentage of patients lost to follow-up were collected. Odds ratios (ORs) and 95% CIs were used as metric of choice for treatment effects with random-effects models. Co-primary endpoints were myocardial infarction and stroke. Key secondary endpoints were all-cause death and vascular death. Heterogeneity

2020 Lancet

6. ASA/ACS/AORN/AHA Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic

ASA/ACS/AORN/AHA Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back (...) Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News April 17, 2020 Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic American College of Surgeons American Society of Anesthesiologists Association of periOperative Registered Nurses American Hospital Association (PDF) Introduction: In response to the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS

2020 American Society of Anesthesiologists

7. The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus

The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back Quality (...) and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News April 29, 2020 The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus (PDF) Patients who are infected with SARS-CoV-2, the virus responsible for the COVID-19 disease, have higher perioperative morbidity and mortality. (1-3) Unexpected progression to acute respiratory distress syndrome, cardiac injury, kidney failure and even deaths has

2020 American Society of Anesthesiologists

8. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI)

Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI) Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) navigation Circulation Actions . 2020 Apr 7;141(14):1141-1151. doi: 10.1161/CIRCULATIONAHA.119.044598. Epub 2020 Mar 17. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada (K.R.B., R.C.W.). 2 Population Heath Research Institute, McMaster University and Hamilton Health Sciences, ON, Canada

2020 EvidenceUpdates

9. APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators

APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators Anesthesia machines are equipped with ventilators that in many cases are capable of providing life-sustaining mechanical ventilation to patients with respiratory failure. They are used for this purpose every day in the operating room. FDA approved labeling does not provide for using anesthesia ventilators for long term ventilatory support. Nevertheless (...) anesthesia machines safely and effectively as ICU ventilators. Detailed information is provided below and a quick reference guide is available for downloading. The quick reference guide is intended to be a bedside tool and includes a suggested schedule for monitoring the effectiveness and safety of the anesthesia ventilator. ASA is working with component societies to develop an inventory of local resources with the goal of moving machines to the locations where they are most needed. (NOTE: Local

2020 American Society of Anesthesiologists

10. Canadian Stroke Best Practice recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events

sequential analysis of randomized controlled trials. Eur Heart J 2019;40:607-17. 7. O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary pre- vention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med 2019 July 23 [Epub ahead of print]. doi: 10.7326/M19-0953. 8. Acetylsalicylic acid (ASA). Whitby (ON): Thrombosis Canada; 2018. Available: https://thrombosiscanada.ca/wp-content/uploads/2019/01/Acetylsalicyclic-Acid (...) % more people die of heart conditions, stroke or vascular cognitive impairment than die from all cancers combined. 1 The benefits of acetylsalicylic acid (ASA) for secondary pre- vention of atherosclerotic cardiovascular disease are well estab- lished. In contrast, although low-dose ASA therapy for primary prevention of atherosclerotic cardiovascular disease was once commonly recommended, this practice is now being recon- sidered in light of recent evidence. Three large randomized con- trolled trials

2020 CPG Infobase

11. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. (Abstract)

Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have (...) a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups. Using Cox proportional-hazards regression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing

2020 NEJM

12. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Full Text available with Trip Pro

Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Comparison of the Effect of Age ( - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 10 Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. PMID: 31924322 DOI: Item in Clipboard Full-text links Cite Abstract The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial

2020 EvidenceUpdates

13. Clopidogrel / Acetylsalicylic acid Mylan

/Acetylsalicylic acid Mylan contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin) and is a ‘generic medicine’. This means that Clopidogrel/Acetylsalicylic acid Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called DuoPlavin. For more information on generic medicines, see the question-and-answer document here. How is Clopidogrel/Acetylsalicylic acid Mylan used? The medicine is available as tablets (...) Clopidogrel / Acetylsalicylic acid Mylan Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/628773/2019 EMEA/H/C/004996 Clopidogrel/Acetylsalicylic acid Mylan (clopidogrel

2020 European Medicines Agency - EPARs

14. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Full Text available with Trip Pro

Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Preterm birth remains a common cause of neonatal mortality, with a disproportionately high burden in low-income and middle-income countries. Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks (...) of gestation.ASPIRIN was a randomised, multicountry, double-masked, placebo-controlled trial of low-dose aspirin (81 mg daily) initiated between 6 weeks and 0 days of pregnancy, and 13 weeks and 6 days of pregnancy, in nulliparous women with an ultrasound confirming gestational age and a singleton viable pregnancy. Participants were enrolled at seven community sites in six countries (two sites in India and one site each in the Democratic Republic of the Congo, Guatemala, Kenya, Pakistan, and Zambia). Participants

2020 Lancet

15. Kaiser Permanente National Aspirin Clinician Guide

Kaiser Permanente National Aspirin Clinician Guide This Clinician Guide expires within two years of the posted month. 1 See National Clinical Library for current version (https://cl.kp.org). Aspirin Clinician Guide October 2018 Introduction These recommendations were developed to assist primary care physicians and other clinicians in aspirin use. The KP National Integrated Cardiovascular Health Guideline team adopted the 2016 aspirin recommendations developed by the United States Preventive (...) Services Task Force (USPSTF) on “Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication” for patients without Atherosclerotic Cardiovascular Disease (ASCVD). It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by practitioners. Aspirin Therapy at 81 mg Orally Daily for Adults without ASCVD Risk Assessment ? 10-year ASCVD Risk is risk of fatal or nonfatal myocardial infarctions or strokes in adults. A region may

2019 Kaiser Permanente National Guideline Program

16. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin Full Text available with Trip Pro

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding.This study sought to explore the effects of the combination of rivaroxaban and aspirin compared with aspirin on sites, timing (...) to the combination of rivaroxaban and aspirin or to aspirin alone and followed for a mean of 23 months. Compared with aspirin alone, the combination increased modified International Society on Thrombosis and Hemostasis major bleeding (288 of 9,152 [3.1%] vs. 170 of 9,126 [1.9%]), (HR: 1.70; 95% CI: 1.40 to 2.05; p < 0.001), International Society on Thrombosis and Hemostasis major bleeding (206 of 9,152 [2.3%] vs. 116 of 9,126 [1.3%]), (HR: 1.78; 95% CI: 1.41 to 2.23; p < 0.0001), and minor bleeding (838 of 9,152

2019 EvidenceUpdates

17. Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines

Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines Last updated: August 19 (...) , 2019 Project Number: RB1368-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness for the use of acetylsalicylic acid in primary prevention of cardiovascular disease? What are the evidence-based guidelines for the use of acetylsalicylic acid in primary prevention of cardiovascular disease? Key Message Twenty-two systematic reviews and meta-analyses, eight randomized controlled trials, and eleven non-randomized studies

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial Full Text available with Trip Pro

Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding. The aim of this study was to estimate the individual lifetime treatment benefit and harm of adding low-dose rivaroxaban to aspirin in patients with stable (...) cardiovascular disease.Patients with established CVD from the COMPASS trial (n = 27 390) and SMART prospective cohort study (n = 8139) were used. Using the pre-existing lifetime SMART-REACH model for recurrent CVD, and a newly developed Fine and Gray competing risk-adjusted lifetime model for major bleeding, individual treatment effects from adding low-dose rivaroxaban to aspirin in patients with stable CVD were estimated, expressed in terms of (i) life-years free of stroke or myocardial infarction (MI

2019 EvidenceUpdates

19. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Full Text available with Trip Pro

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants (...) with stable cardiovascular disease and peripheral artery disease randomly assigned to groups given pantoprazole (40 mg daily, n = 8791) or placebo (n = 8807). Participants were also randomly assigned to groups that received rivaroxaban (2.5 mg twice daily) with aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg) alone. We collected data on development of pneumonia, Clostridium difficile infection, other enteric infections, fractures, gastric atrophy, chronic kidney disease

2019 EvidenceUpdates

20. Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines

Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness (...) and Guidelines Last updated: January 21, 2019 Project Number: RA1006-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the comparative clinical effectiveness of topical cantharidin/salicylic acid/podophyllin versus other topical treatments for warts? What are the evidence-based guidelines for the topical treatment of warts? Key Message One non-randomized study and two evidence-based guidelines were identified regarding topical cantharidin/ salicylic acid

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review